R Dolin, BS Graham, SB Greenberg, CO Tacket … - Annals of internal medicine, 1991 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Objective: To evaluate the safety and immunogenicity of a human ... Cited by 85 - Related articles - All 3 versions
RB Belshe, ML Clements, R Dolin, BS Graham, … - The Journal of infectious diseases, 1993 - jstor.org Saint Louis University School of Medicine, St. Louis, Missouri; Johns Hopkins
School of Hygiene and Public Health and School of Medicine, Baltimore, EMMES
Corporation, Potomac, and the National Institute of Allergy and Infectious ... Cited by 34 - Related articles - BL Direct - All 3 versions
BS Graham, TJ Matthews, RB Belshe, ML … - The Journal of infectious diseases, 1993 - ncbi.nlm.nih.gov Twelve vaccinia-naive volunteers were inoculated with recombinant vaccinia virus
expressing the human immunodeficiency virus type 1 (HIV-1) strain IIIB
(HIV-1IIIB) envelope glycoprotein gp160 and subsequently immunized with 640 ... Cited by 91 - Related articles - BL Direct - All 2 versions
DH Schwartz, G Gorse, ML Clements, R Belshe, … - Lancet(British edition), 1993 - cat.inist.fr Induction of HIV-1-neutralising and syncytium-inhibiting antibodies in uninfected
recipients of HIV-1 IIIB rgp 120 subunit vaccine. ... Cited by 72 - Related articles - BL Direct - All 4 versions
- ►annals.org BS Graham, MC Keefer, MJ McElrath, GJ Gorse, … - Annals of internal medicine, 1996 - Am Coll Physicians Interventions: In part A of the study, 32 participants were randomly assigned to
receive either 15 µg of rgp120 in MF59, 15 µg of rgp120 in MF59 plus 50 µg of
MTP-PE, 50 µg of rgp120 in MF59, or 50 µg of rgp120 in MF59 plus 50 µg ... Cited by 67 - Related articles - BL Direct - All 3 versions
RR Redfield, DL Birx, N Ketter, E Tramont, V … - New England Journal of Medicine, 1991 - content.nejm.org BACKGROUND. Despite multiple antiviral humoral and cellular immune responses,
infection with the human immunodeficiency virus (HIV) results in a progressively
debilitating disease. We hypothesized that a more effective immune response ... Cited by 136 - Related articles - All 4 versions
MC KEEFER, BS GRAHAM, RB BELSHE, D … - AIDS research and human retroviruses, 1994 - liebertonline.com Page 1. AIDS RESEARCH AND HUMAN RETROVIRUSES Volume 10, Number 12, 1994
Mary Ann Liebert, Inc., Publishers Studies of High Doses ... Cited by 43 - Related articles - BL Direct - All 3 versions
RB Belshe, BS Graham, MC Keefer, GJ Gorse, … - Jama, 1994 - Am Med Assoc OBJECTIVE--To evaluate the safety and immunogenicity of the MN strain of
recombinant gp120 (MN rgp120) as a vaccine prototype to prevent human
immunodeficiency virus (HIV). DESIGN--Double-blind, randomized, placebo- ... Cited by 93 - Related articles - BL Direct - All 3 versions
BS Graham, GJ Gorse, DH Schwartz, MC Keefer … - The Journal of infectious diseases, 1994 - jstor.org Bristol-Myers/Squibb Pharmaceutical Research Institute and University of
Washington School of Medicine, Seattle, Washington; MicroGeneSys, Inc., Meriden,
Connecticut; Johns Hopkins School of Hygiene and Public Health and School ... Cited by 27 - Related articles - BL Direct - All 3 versions
J Wintsch, CL Chaignat, DG Braun, M Jeannet, … - The Journal of infectious diseases, 1991 - jstor.org Safety and Immunogenicity of a Genetically Engineered Human ... Department of
Medicine, University Hospital, Geneva, and Ciba-Geigy Ltd., Basel, Switzerland;
Chiron Research Laboratories, Emeryville, California Cited by 46 - Related articles - All 3 versions
